Entering text into the input field will update the search result below

Novartis' serelaxin flunks late-state heart failure study; shares ease a fraction premarket

Mar. 22, 2017 8:06 AM ETNovartis AG (NVS) StockNVSBy: Douglas W. House, SA News Editor
  • Novartis (NYSE:NVS) is off a fraction premarket on light volume in response to its announcement that a Phase 3 clinical trial, RELAX-AHF-2, evaluating RLX030 (serelaxin) in patients with acute heart failure failed to achieve the primary endpoint of a statistically valid reduction in cardiovascular death through day 180 or reduced worsening heart failure through day 5 when added to standard therapy.
  • Global Head, Drug Development and Chief Medical Officer Vas Narasimhan says, "We are disappointed this study did not confirm the efficacy of RLX030 in acute heart failure, especially given the urgent need for effective new treatments for this condition. We will continue to further analyze the data to better understand and learn from these results as well as evaluate next steps for the overall program."
  • RLX030, a relaxin receptor agonist, is a recombinant form of the naturally occurring hormone human relaxin-2. It is present in both men and women, but elevated in pregnant women and is thought to help the body cope with additional cardiovascular demands during pregnancy.

Recommended For You

More Trending News

About NVS Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
NVS--
Novartis AG